Literature DB >> 6181668

Dipyridamole is an interferon inducer.

A S Galabov, M Mastikova.   

Abstract

2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido-[5,4-d]-pyrimidine (dipyridamole) induced interferon production in vitro in explanted mouse peritoneal leukocytes and to a lower degree in non-lymphoidal cell cultures of mouse (L cells primary embryo fibroblasts) and human (diploid embryo lung fibroblasts) origin. Dipyridamole induced interferon also in mice after intravenous administration. Peak interferon levels in the blood (128 IU/ml) were attained at 49 hr after injection of 0.1 mg dipyridamole per kg body weight and at 24 and 12 hr after injection of 0.6-1.8 and 16.7 mg/kg respectively. By its pH stability, thermostability and antigenic properties the interferon induced in mice, mouse peritoneal leukocytes and L cells corresponded to IFN-alpha and IFN-beta. This interferon-inducing capacity of dipyridamole may account for its broad-spectrum antiviral effect.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181668

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  6 in total

1.  Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.

Authors:  J Szebeni; S M Wahl; M Popovic; L M Wahl; S Gartner; R L Fine; U Skaleric; R M Friedmann; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole.

Authors:  M Barberi-Heyob; G Griffon; J L Merlin; B Weber
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Effect of dipyridamole on zidovudine pharmacokinetics and short-term tolerance in asymptomatic human immunodeficiency virus-infected subjects.

Authors:  C W Hendrix; C Flexner; J Szebeni; S Kuwahara; S Pennypacker; J N Weinstein; P S Lietman
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 4.  Nucleoside salvage and resistance to antimetabolite anticancer agents.

Authors:  M Fox; J M Boyle; A R Kinsella
Journal:  Br J Cancer       Date:  1991-09       Impact factor: 7.640

Review 5.  The Adenosine Pathway and Human Immunodeficiency Virus-Associated Inflammation.

Authors:  Emily A Hixson; Priya V Borker; Edwin K Jackson; Bernard J Macatangay
Journal:  Open Forum Infect Dis       Date:  2021-07-24       Impact factor: 3.835

6.  Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.